文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌患者适合柔性输尿管镜钬激光消融的条件:大容量中心长期结果

Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution.
PubMed 文献 · J Urol · 2017-08-15

单中心92例上尿路尿路上皮癌患者接受柔性输尿管镜钬激光消融,中位随访52个月。肿瘤大小>1 cm与多灶性未增加进展风险,而高分级是疾病进展的唯一独立预测因素(HR 5.16)。

要点

  • 高分级肿瘤独立降低无进展生存率(HR 5.16,95%CI 1.19-22.26,p=0.03)。
  • 肿瘤大小≤1 cm vs >1 cm的无进展生存率68% vs 72%(p=0.9),无显著差异。
  • 单灶 vs 多灶的无进展生存率72% vs 69%(p=0.6),无显著差异。

核心结论

  • 高分级肿瘤独立降低接受钬激光消融的上尿路尿路上皮癌患者的无进展生存率。
  • 肿瘤大小>1 cm和多灶性并未增加接受钬激光消融保守治疗患者的疾病进展风险。

研究设计与样本

  • 单中心三级转诊中心连续纳入92例上尿路尿路上皮癌患者,2003年至2015年接受柔性输尿管镜钬激光消融。
  • 根据EAU指南进行严格随访,进展定义为肿瘤分级升高、远处转移和/或保守方法无法完全切除的复发肿瘤。
  • 采用Kaplan-Meier曲线评估进展率,Cox回归分析临床和病理特征对无进展生存率的影响。

主要发现

  • 中位随访52个月(IQR 27.8-76.4),肿瘤大小≤1 cm组 vs >1 cm组的无进展生存率分别为68% vs 72%(p=0.9)。
  • 单灶组 vs 多灶组的无进展生存率分别为72% vs 69%(p=0.6)。
  • 低分级组 vs 高分级组的无进展生存率分别为75% vs 52%(p=0.03)。
  • 多变量Cox回归分析显示,首次治疗时肿瘤分级是疾病进展的唯一独立预测因素(HR 5.16,95%CI 1.19-22.26,p=0.03)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We tested the effects of tumor size, distribution and grade on progression-free survival in patients with upper tract urothelial carcinoma treated with flexible ureteroscopy with Ho:YAG laser photoablation. MATERIALS AND METHODS: Included in analysis were data on 92 consecutive patients with upper tract urothelial carcinoma treated with Ho:YAG laser photoablation from 2003 to 2015 at a single tertiary care referral center. Stringent followup was offered according to EAU (European Association of Urology) guidelines. Progression during followup was defined by tumor upgrading, distant metastases and/or a relapsing tumor that could not be completely removed with a conservative approach. Kaplan-Meier curves were used to assess the rate of disease progression according to tumor size (1 or less cm vs greater than 1 cm), tumor distribution (unifocal vs multifocal) and tumor grade (low vs high). Cox regression analysis was done to test the impact of clinical and pathological characteristics on the rate of progression-free survival. RESULTS: At a median followup of 52 months (IQR 27.8-76.4) the progression-free survival rate was 68% vs 72% in patients with a tumor size of 1 or less vs greater than 1 cm (p = 0.9), 72% vs 69% in patients with unifocal vs multifocal lesions (p = 0.6) and 75% vs 52% in patients with a low vs a high grade tumor (p = 0.03). On multivariable Cox regression analysis tumor grade at first treatment was the only independent predictor of disease progression (HR 5.16, 95% CI 1.19-22.26, p = 0.03). CONCLUSIONS: High tumor grade independently decreased progression-free survival in patients with upper tract urothelial carcinoma treated with Ho:YAG laser photoablation. Tumor size greater than 1 cm and multifocality did not increase the risk of disease progression in patients treated conservatively with Ho:YAG laser photoablation.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Villa L, Haddad M, Capitanio U, et al. Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. J Urol. 2017. PMID: 28818526. doi:10.1016/j.juro.2017.07.088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。